Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dalma Seboek

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Endocrinology|March 12, 2005
Autocrine/paracrine role of inflammation-mediated calcitonin gene-related peptide and adrenomedullin expression in human adipose tissuePhilippe Linscheid, Dalma Seboek, Henryk Zulewski, et al.
Pharmaceutical Medicine|June 7, 2023
Meaningful Within-Patient Change on the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ): Analysis of Phase III Clinical Trial Data of DaridorexantAndrea Phillips-Beyer, Ariane K Kawata, Leah Kleinman, et al.
Advances in Therapy|April 26, 2023
Summary of Research: Development and Validation of the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ)Stacie Hudgens, Andrea Phillips-Beyer, Louise Newton, et al.
The Patient|November 1, 2020
Development and Validation of the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ)Stacie Hudgens, Andrea Phillips-Beyer, Louise Newton, et al.
Critical Care Medicine|August 3, 2004
Expression and secretion of procalcitonin and calcitonin gene-related peptide by adherent monocytes and by macrophage-activated adipocytesPhilippe Linscheid, Dalma Seboek, Dominik J Schaer, et al.
Sleep|September 2, 2022
Preferences of patients for benefits and risks of insomnia medications using data elicited during two phase III clinical trialsSebastian Heidenreich, Melissa Ross, Gin Nie Chua, et al.
Pharmaceutical Medicine|February 1, 2024
Meaningful Within-Patient Change in Subjective Total Sleep Time in Patients with Insomnia Disorder: An Analysis of the Sleep Diary Questionnaire Using Data from Open-Label and Phase III Clinical TrialsAndrea Phillips-Beyer, Ariane K Kawata, Leah Kleinman, et al.
American Journal of Physiology. Endocrinology and Metabolism|December 29, 2005
Cytokine-induced metabolic effects in human adipocytes are independent of endogenous nitric oxidePhilippe Linscheid, Dalma Seboek, Henryk Zulewski, et al.
Annals of Neurology|January 19, 2020
Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia DisorderYves Dauvilliers, Gary Zammit, Ingo Fietze, et al.
The Journal of Clinical Endocrinology and Metabolism|October 9, 2004
Somatostatin is expressed and secreted by human adipose tissue upon infection and inflammationDalma Seboek, Philippe Linscheid, Henryk Zulewski, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Endocrinology|March 12, 2005
Autocrine/paracrine role of inflammation-mediated calcitonin gene-related peptide and adrenomedullin expression in human adipose tissuePhilippe Linscheid, Dalma Seboek, Henryk Zulewski, et al.
Pharmaceutical Medicine|June 7, 2023
Meaningful Within-Patient Change on the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ): Analysis of Phase III Clinical Trial Data of DaridorexantAndrea Phillips-Beyer, Ariane K Kawata, Leah Kleinman, et al.
Advances in Therapy|April 26, 2023
Summary of Research: Development and Validation of the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ)Stacie Hudgens, Andrea Phillips-Beyer, Louise Newton, et al.
The Patient|November 1, 2020
Development and Validation of the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ)Stacie Hudgens, Andrea Phillips-Beyer, Louise Newton, et al.
Critical Care Medicine|August 3, 2004
Expression and secretion of procalcitonin and calcitonin gene-related peptide by adherent monocytes and by macrophage-activated adipocytesPhilippe Linscheid, Dalma Seboek, Dominik J Schaer, et al.
Sleep|September 2, 2022
Preferences of patients for benefits and risks of insomnia medications using data elicited during two phase III clinical trialsSebastian Heidenreich, Melissa Ross, Gin Nie Chua, et al.
Pharmaceutical Medicine|February 1, 2024
Meaningful Within-Patient Change in Subjective Total Sleep Time in Patients with Insomnia Disorder: An Analysis of the Sleep Diary Questionnaire Using Data from Open-Label and Phase III Clinical TrialsAndrea Phillips-Beyer, Ariane K Kawata, Leah Kleinman, et al.
American Journal of Physiology. Endocrinology and Metabolism|December 29, 2005
Cytokine-induced metabolic effects in human adipocytes are independent of endogenous nitric oxidePhilippe Linscheid, Dalma Seboek, Henryk Zulewski, et al.
Annals of Neurology|January 19, 2020
Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia DisorderYves Dauvilliers, Gary Zammit, Ingo Fietze, et al.
The Journal of Clinical Endocrinology and Metabolism|October 9, 2004
Somatostatin is expressed and secreted by human adipose tissue upon infection and inflammationDalma Seboek, Philippe Linscheid, Henryk Zulewski, et al.
Pageof 2